Participant flow

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma · Source last updated 2016-07-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Induction Cycles 1-3: Methotrexate 8gm/m\^2 days 1 \& 15; Leucovorin 100 mg/m\^2 days 2 \& 16; Rituximab 375 mg/m\^2 days 3, 10, 17 \& 24 of cycle 1, days 3 \& 10 of cycle 2; Temozolomide 150 mg/m\^2/day PO days 7-11 Induction Cycle 4: Temozolomide 150 mg/m\^2/day PO days 7-11; Methotrexate 8gm/m\^2 day 15; Leucovorin 100 mg/m\^2 day 16 Consolidation Cycle 5: Methotrexate 8gm/m\^2 days 1; Leucovorin 100 mg/m\^2 days 2; Temozolomide 150 mg/m\^2/day PO days 7-11 Consolidation Cycle 6: Cytarabine 2 g/m\^2 (x 8 doses) days 1-4; Etoposide 5 mg/kg (x 8 doses) days 1-4; G-CSF 5 mcg/kg/day or GM-CSF 250 mcg/m\^2/day starting day 14 until ANC recovers (\>= 500 for 2 consecutive days or \>= 1500 for one day)

   id

   FG000

   title

   Intensive Combination Chemo & Immunotherapy

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         9

      type

      Disease Progression

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Withdrawal by Subject

   4. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Failed (to respond) during induction

   5. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Physician Decision

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         44

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         26

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         18

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Three participants were excluded from analysis because of failure to meet eligibility criteria or to receive protocol therapy.

recruitment Details

Between October 2004 and November 2009, 47 participants were recruited at 12 CALGB sites.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice